On December 22, 2022, Health Canada opened consultation on a proposal to amend the Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs). The […] Read More >>
On December 16, 2022, Health Canada issued a notice to stakeholders regarding their proposal to amend the regulations for Biologic Drugs (Schedule D drugs) in Division 4, Part C, of […] Read More >>
By: Clara Di Tella, BSc, Pharm QA – Regulatory Affairs Specialist January 30, 2012 Last spring, Health Canada consulted with stakeholders and the public on various options for policies for […] Read More >>